{
  "variant": {
    "gene": "SNCA",
    "protein_change": {
      "ref": "A",
      "alt": "P",
      "position": 30
    },
    "variant_string_id": "SNCA A30P"
  },
  "acmg_flowchart": {
    "step_1": {
      "question": "Define the disease mechanism.",
      "answer": "Yes",
      "justification": "The paper explicitly states that Lewy bodies (composed of a-synuclein fibrils) are the hallmark of Parkinson's disease, and the study focuses on how mutations affect aggregation and structural changes."
    },
    "step_2": {
      "question": "Evaluate applicability of the assay.",
      "answer": "Yes",
      "justification": "The assay (quenched H/D exchange and NMR spectroscopy) directly investigates structural changes in a-synuclein fibrils, which are central to the disease mechanism."
    },
    "step_3": {
      "substep_3a": {
        "question": "Basic controls (e.g., wild-type comparison).",
        "answer": "Yes",
        "justification": "The study compares A30P to wild-type a-synuclein, as indicated by the conclusion that A30P does not alter fibril structure."
      },
      "substep_3b": {
        "question": "Accepted/validated assay.",
        "answer": "Yes",
        "justification": "Quenched H/D exchange and NMR are standard techniques for studying protein structure and dynamics in fibrils."
      },
      "substep_3c": {
        "question": "Variant controls (e.g., other mutations as positive/negative controls).",
        "answer": "No",
        "justification": "The paper focuses on A30P and does not explicitly mention other variants (e.g., E46K, A53T) as controls in the abstract or methods described."
      }
    },
    "step_4": {
      "substep_4a": {
        "question": "Statistical analyses (OddsPath calculation).",
        "answer": "No",
        "justification": "The abstract does not mention p-values, effect sizes, or explicit OddsPath calculations."
      },
      "substep_4b": {
        "question": "Number of benign/pathogenic variant controls.",
        "answer": "1",
        "justification": "The study uses wild-type a-synuclein as a control, but no additional variants are explicitly listed."
      },
      "substep_4c": {
        "question": "Correlate OddsPath (if applicable).",
        "answer": "Not applicable",
        "justification": "No OddsPath values are reported in the provided text."
      }
    },
    "final_evidence": {
      "strength": "PS3_supporting",
      "justification": "The assay is validated (Step 3b), but no OddsPath calculations or extensive variant controls are reported (Steps 4a-b). The study's conclusion that A30P does not alter fibril structure suggests limited functional impact, supporting a 'supporting' level of evidence for pathogenicity."
    }
  }
}